Skip to main content
SpringerLink
Log in

Lesinurad in hyperuricaemia of gout: a profile of its use in the EU

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption inhibitor lesinurad (Zurampic®) is an effective and generally well tolerated option for the adjunctive treatment of hyperuricaemia in patients with gout who have not achieved target serum uric acid (sUA) levels with monotherapy with an adequate dosage of a xanthine oxidase inhibitor, a class of drugs that acts on UA production. In phase 3 trials of lesinurad + allopurinol in adults with gout inadequately responsive to allopurinol, and lesinurad + febuxostat in adults with tophaceous gout, the addition of once-daily oral lesinurad enabled many patients to achieve target sUA levels, and improved clinical parameters (e.g. tophus number/size) in the long term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology. 2017;56(7):1246. https://doi.org/10.1093/rheumatology/kex156.

    Article  CAS  PubMed  Google Scholar 

  2. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–52.

    Article  CAS  Google Scholar 

  3. Bardin T, Richette P. Novel uricosurics. Rheumatology. 2018;57:i42–i46.

    Article  Google Scholar 

  4. Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2010;64(3):371–7.

    Article  CAS  Google Scholar 

  5. Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177–82.

    Article  CAS  Google Scholar 

  6. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.

    Article  CAS  Google Scholar 

  7. Zurampic 200 mg film-coated tablets: EU summary of product characteristics. London: European Medicines Agency; 2017.

  8. Zurampic® (lesinurad) tablets for oral use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.

  9. Duzallo (allopurinol and lesinurad 200 mg/200 mg and 300 mg/200 mg) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2018.

  10. Xin Y, Wang K, Jia Z, et al. Zurampic protects pancreatic β-cells from high uric acid induced-damage by inhibiting URAT1 and inactivating the ROS/AMPK/ERK pathways. Cell Physiol Biochem. 2018;47(3):1074–83.

    Article  CAS  Google Scholar 

  11. Miner J, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214.

    Article  Google Scholar 

  12. Shen Z, Rowlings C, Kerr B, et al. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Des Devel Ther. 2015;9:3423–34.

    Article  CAS  Google Scholar 

  13. Baumgartner S, Yeh LT, Shen Z, et al. The effect of lesinurad in combination with allopurinol on serum uric acid levels in patients with gout. J Clin Pharmacol. 2018;58(9):1164–70.

    Article  CAS  Google Scholar 

  14. Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology. 2014;53(12):2167–74.

    Article  CAS  Google Scholar 

  15. Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074–80.

    Article  CAS  Google Scholar 

  16. Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76(5):811–20.

    Article  CAS  Google Scholar 

  17. Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69(1):203–12.

    Article  CAS  Google Scholar 

  18. Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69(9):1903–13.

    Article  CAS  Google Scholar 

  19. Saag KG, Bardin T, So A, et al. Analysis of gout subjects receiving lesinurad and allopurinol combination therapy by baseline renal function [abstract no. 2112]. Arthritis Rheumatol. 2015;67(Suppl 10).

  20. Bardin T, Karra RG, So A, et al. Lesinurad (LESU) adjunctive therapy with allopurinol (ALLO) in patients not responding to ALLO monotherapy: pooled post hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline (BL) [abstract no. SAT0374]. Ann Rheum Dis. 2018;77(Suppl 2):1050.

  21. Bardin T, Dalbeth N, Terkeltaub R, et al. Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract no. 209]. Arthritis Rheumatol. 2016;68(Suppl 10).

  22. Saag KG, Becker MA, Storgard C, et al. Examination of serum uric acid (SUA) lowering and safety with extended treatment with lesinurad and allopurinol in subjects with gout [abstract no. THU0495]. Ann Rheum Dis. 2016;75(Suppl 2):371.

    Article  Google Scholar 

  23. Terkeltaub R, Saag KG, Goldfarb DS, et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology. 2018. https://doi.org/10.1093/rheumatology/key245.

  24. Terkeltaub R, Malamet R, Bos K, et al. Renal safety of lesinurad: a pooled analysis of phase III and extension studies [abstract no. THU0455]. Ann Rheum Dis. 2017;76 (Suppl 2):379–80.

  25. Klein RW, Kabadi S, Cinfio FN, et al. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective. J Comp Eff Res. 2018. https://doi.org/10.2217/cer-2017-0103.

  26. Ruggeri M, Basile M, Drago C, et al. Cost-effectiveness analysis of lesinurad/allopurinol versus febuxostat for the management of gout/hyperuricemia in Italy. Pharmacoeconomics. 2018;36(5):625–36.

    Article  CAS  Google Scholar 

  27. Perez-Ruiz F, Kandaswamy P, Karra Gurunath R, et al. A summary of clinical evidence for commonly used uricosurics for gout in Europe [abstract no. SAT0360]. Ann Rheum Dis. 2018;77(Suppl 2):1045.

  28. Deeks ED. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging. 2017;34(5):401–10.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The manuscript was updated from Drugs & Aging 2017;34(5):401–1 [28], and was reviewed by: M. Bleckwenn, Institut für Hausarztmedizin, Medizinischen Fakultät der Universität Bonn, Bonn, Germany; A.L. Gaffo, University of Alabama at Birmingham, and Rheumatology Section, Birmingham VA Medical Center, Birmingham, AL, USA; M.J. Puszczewicz, Department of Rheumatology and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland; L. Roever, Clinical Research Department, Federal University of Uberlândia, Uberlândia, Brazil. During the peer review process, Grunenthal, the marketing-authorization holder of lesinurad, was also offered an opportunity to provide a scientific accuracy review of the data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Hannah A. Blair & Emma D. Deeks

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

H. A. Blair and E. D. Deeks are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A., Deeks, E.D. Lesinurad in hyperuricaemia of gout: a profile of its use in the EU. Drugs Ther Perspect 34, 560–566 (2018). https://doi.org/10.1007/s40267-018-0566-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0566-3

Search

Navigation